Research2Reality and Bayer Inc. work together to film innovative research

Gairdner Foundation


Research2Reality (R2R) is pleased to announce that they are working together with Bayer Inc. to document how Bayer supports innovation in Canada through academic and industry collaborations. The program includes production of three documentary videos to illustrate how innovative thinking and collaboration has led to breakthroughs in medical research and the successful development of new treatments.

Innovation is an integral part of the vision and strategy of Bayer globally and it is reflected in not just solutions to healthcare challenges but to Bayer as an organization.

“At Bayer, we are committed to innovation leadership in solving problems in healthcare, nutrition and quality of life around the world,” says Dr. Shurjeel Choudhri, Senior Vice President and Head, Medical & Scientific Affairs. “By understanding both the research process and the documentary approach to video production, the R2R team brings a unique combination of skills to help us tell our story of how Bayer collaborates to promote research innovation in Canada.”

University of Toronto University Professor and Officer of the Order of Canada Dr. Molly Shoichet, who co-Founded R2R, says “We are delighted to be working with Bayer to highlight brilliant Canadian research and innovation. We take advantage of the power of film to tell compelling research stories. We tell one story based on the successful development of a treatment regime for patients with coronary artery disease to prevent heart attack, stroke or death and another based on the tumour agnostic treatment for advanced solid tumours that harbour an NTRK gene fusion. We engage the public with these life-changing research stories.”

About Bayer: Science For A Better Life

Bayer is a global enterprise with core competencies in the life science fields of health care and nutrition. Its products and services are designed to benefit people by supporting efforts to overcome the major challenges presented by a growing and aging global population. At the same time, the Group aims to increase its earning power and create value through innovation and growth. Bayer is committed to the principles of sustainable development, and the Bayer brand stands for trust, reliability and quality throughout the world. In fiscal 2019, the Group employed around 104,000 people and had sales of 43.5 billion euros. Capital expenditures amounted to 2.9 billion euros, R&D expenses to 5.3 billion euros. For more information, go to